Our Insights Chronic Disease Anthony Iannacci 9/2/26 Chronic Disease Anthony Iannacci 9/2/26 Cytokinetics’ Myqorzo is On Track For a Significant Label Expansion into nHCM, Where In-Class Rival Camzyos Failed. Payers are the Next Challenge. Read More Chronic Disease Anthony Iannacci 7/28/26 Chronic Disease Anthony Iannacci 7/28/26 Lipfendra Brings PCSK9i Efficacy with Oral Convenience Read More Chronic Disease Anthony Iannacci 3/31/26 Chronic Disease Anthony Iannacci 3/31/26 Oveporexton Could be a Game-changer for Narcolepsy Type 1 Read More Chronic Disease Anthony Iannacci 2/17/26 Chronic Disease Anthony Iannacci 2/17/26 Gene Therapies for Sickle Cell Disease: Expensive but Worth It Read More Chronic Disease Anthony Iannacci 1/8/26 Chronic Disease Anthony Iannacci 1/8/26 Using Equinox Drivers Charts to Understand Fabhalta's Success in PNH Read More Chronic Disease Anthony Iannacci 9/16/25 Chronic Disease Anthony Iannacci 9/16/25 Journavx, a vast improvement over opioids in moderate acute pain Read More Chronic Disease Anthony Iannacci 3/20/24 Chronic Disease Anthony Iannacci 3/20/24 Xolair for food allergies: effective therapy at a high price Read More Chronic Disease Anthony Iannacci 3/4/24 Chronic Disease Anthony Iannacci 3/4/24 Monoclonal antibodies for Alzheimer’s disease: questionable clinical benefit at a high price Read More Chronic Disease Anthony Iannacci 8/29/23 Chronic Disease Anthony Iannacci 8/29/23 Evrysdi: A Potential Game-Changer for SMA Type 1 Patients Read More Chronic Disease Anthony Iannacci 7/26/22 Chronic Disease Anthony Iannacci 7/26/22 Prospects for ulotaront in schizophrenia Read More Chronic Disease Anthony Iannacci 7/15/20 Chronic Disease Anthony Iannacci 7/15/20 Trikafta: A Major Step Forward for Cystic Fibrosis Patients Read More Chronic Disease Anthony Iannacci 6/11/19 Chronic Disease Anthony Iannacci 6/11/19 Radicava: Not Innovative Enough to Sustain Strong Start Read More Chronic Disease Anthony Iannacci 3/29/19 Chronic Disease Anthony Iannacci 3/29/19 Hemlibra: A Strong Leader in Hemophilia A Read More Chronic Disease Anthony Iannacci 3/7/19 Chronic Disease Anthony Iannacci 3/7/19 Oral semaglutide: A game changer in type 2 diabetes Read More Chronic Disease Anthony Iannacci 2/6/19 Chronic Disease Anthony Iannacci 2/6/19 Tymlos: A new force in the osteoporosis market Read More Chronic Disease Anthony Iannacci 2/6/19 Chronic Disease Anthony Iannacci 2/6/19 Xeljanz: Is ulcerative colitis finally the place for JAKs to shine? Read More Chronic Disease Anthony Iannacci 10/23/15 Chronic Disease Anthony Iannacci 10/23/15 Gilenya, Aubagio, and Tecfidera in Multiple Sclerosis Read More Chronic Disease Anthony Iannacci 9/5/15 Chronic Disease Anthony Iannacci 9/5/15 Jardiance: New outcomes data in type 2 diabetes Read More Chronic Disease Anthony Iannacci 2/20/14 Chronic Disease Anthony Iannacci 2/20/14 Brintellix: Another "me too" in major depression Read More Chronic Disease Anthony Iannacci 10/29/13 Chronic Disease Anthony Iannacci 10/29/13 Pradaxa: Stroke prevention in atrial fibrillation Read More Older Posts
Chronic Disease Anthony Iannacci 9/2/26 Chronic Disease Anthony Iannacci 9/2/26 Cytokinetics’ Myqorzo is On Track For a Significant Label Expansion into nHCM, Where In-Class Rival Camzyos Failed. Payers are the Next Challenge. Read More
Chronic Disease Anthony Iannacci 7/28/26 Chronic Disease Anthony Iannacci 7/28/26 Lipfendra Brings PCSK9i Efficacy with Oral Convenience Read More
Chronic Disease Anthony Iannacci 3/31/26 Chronic Disease Anthony Iannacci 3/31/26 Oveporexton Could be a Game-changer for Narcolepsy Type 1 Read More
Chronic Disease Anthony Iannacci 2/17/26 Chronic Disease Anthony Iannacci 2/17/26 Gene Therapies for Sickle Cell Disease: Expensive but Worth It Read More
Chronic Disease Anthony Iannacci 1/8/26 Chronic Disease Anthony Iannacci 1/8/26 Using Equinox Drivers Charts to Understand Fabhalta's Success in PNH Read More
Chronic Disease Anthony Iannacci 9/16/25 Chronic Disease Anthony Iannacci 9/16/25 Journavx, a vast improvement over opioids in moderate acute pain Read More
Chronic Disease Anthony Iannacci 3/20/24 Chronic Disease Anthony Iannacci 3/20/24 Xolair for food allergies: effective therapy at a high price Read More
Chronic Disease Anthony Iannacci 3/4/24 Chronic Disease Anthony Iannacci 3/4/24 Monoclonal antibodies for Alzheimer’s disease: questionable clinical benefit at a high price Read More
Chronic Disease Anthony Iannacci 8/29/23 Chronic Disease Anthony Iannacci 8/29/23 Evrysdi: A Potential Game-Changer for SMA Type 1 Patients Read More
Chronic Disease Anthony Iannacci 7/26/22 Chronic Disease Anthony Iannacci 7/26/22 Prospects for ulotaront in schizophrenia Read More
Chronic Disease Anthony Iannacci 7/15/20 Chronic Disease Anthony Iannacci 7/15/20 Trikafta: A Major Step Forward for Cystic Fibrosis Patients Read More
Chronic Disease Anthony Iannacci 6/11/19 Chronic Disease Anthony Iannacci 6/11/19 Radicava: Not Innovative Enough to Sustain Strong Start Read More
Chronic Disease Anthony Iannacci 3/29/19 Chronic Disease Anthony Iannacci 3/29/19 Hemlibra: A Strong Leader in Hemophilia A Read More
Chronic Disease Anthony Iannacci 3/7/19 Chronic Disease Anthony Iannacci 3/7/19 Oral semaglutide: A game changer in type 2 diabetes Read More
Chronic Disease Anthony Iannacci 2/6/19 Chronic Disease Anthony Iannacci 2/6/19 Tymlos: A new force in the osteoporosis market Read More
Chronic Disease Anthony Iannacci 2/6/19 Chronic Disease Anthony Iannacci 2/6/19 Xeljanz: Is ulcerative colitis finally the place for JAKs to shine? Read More
Chronic Disease Anthony Iannacci 10/23/15 Chronic Disease Anthony Iannacci 10/23/15 Gilenya, Aubagio, and Tecfidera in Multiple Sclerosis Read More
Chronic Disease Anthony Iannacci 9/5/15 Chronic Disease Anthony Iannacci 9/5/15 Jardiance: New outcomes data in type 2 diabetes Read More
Chronic Disease Anthony Iannacci 2/20/14 Chronic Disease Anthony Iannacci 2/20/14 Brintellix: Another "me too" in major depression Read More
Chronic Disease Anthony Iannacci 10/29/13 Chronic Disease Anthony Iannacci 10/29/13 Pradaxa: Stroke prevention in atrial fibrillation Read More
